Chemical genomics in yeast
© BioMed Central Ltd 2004
Published: 27 August 2004
Skip to main content
© BioMed Central Ltd 2004
Published: 27 August 2004
Many drugs have unknown, controversial or multiple mechanisms of action. Four recent 'chemical genomic' studies, using genome-scale collections of yeast gene deletions that were either arrayed or barcoded, have presented complementary approaches to identifying gene-drug and pathway-drug interactions.
The fact that much of modern drug research is target-oriented obscures the long history during which the effects of drugs were discovered prior to identification of their targets. There remain many natural products and drugs for which the cellular target protein(s) are yet to be fully characterized. Without the identification of specific targets, it is extremely difficult to modify and improve the performance of drugs and to determine whether side effects are due to effects on the primary target or 'off target' effects. Indeed, mouse-on-the-hotplate analgesia assays  seem crude in this era of high-throughput screening and structure-based refinement of, for example, inhibitors of cyclooxygenase 2 (COX-2) . But the advantage of targetless whole-animal assays is that compounds that would pass some early stage of in vitro screening, only later to fail to have in vivo efficacy, do not score positively in whole-animal assays. This is important because acceleration of failure is considered to be a cost- and time-conserving necessity in drug discovery.
There is clearly a need to work through the legacy compound collections owned by pharmaceutical companies. In addition, the introduction of zebrafish  and invertebrate  systems into drug screening (for the advantages cited above for mouse assays) will ensure that there is an ongoing need for genetic and genomic strategies that can identify the targets of pharmacologically interesting small molecules. Because no eukaryotic model system is more genetically advanced than the budding yeast Saccharomyces cerevisiae and because fungi contain substantial numbers of orthologs of human drug targets, baker's yeast is an obviously place to start to identify drug mechanisms of action. Four recent papers [5–8] make important contributions to mapping drug effects using yeast genomics.
Before reviewing recent work, it is useful to consider a number of ways in which a drug might inhibit the division, growth or survival of yeast cells. Conceptually, the simplest mechanism is that a drug inhibits an enzyme essential for cell division and growth, such as a replicative DNA polymerase. If this were the case, then the primary target of the drug is expected to be encoded by an essential gene, such that one could select for dominant resistant mutants in haploid or diploid cells; but one could not easily conduct a screen that would depend on recovery of haploid loss-of-function mutants in the target gene because such cells are expected to be nonviable. Because a collection of all potential dominant mutants would have many more members than the total number of genes (and, in fact, many more than the total number of codons), there is no standing genetic resource for such drug selections in any organism. Typically, a researcher interested in selecting for dominant drug-resistant mutants will mutagenize cells anew and plate many millions of such cells for resistant colonies.
In the case of replicative polymerases, many drugs that act on these proteins are actually pro-drugs, compounds that depend on cellular enzymes for conversion to the active inhibitory agents. Thus, for azidothymidine or dideoxyinosine to inhibit their intended targets (reverse transcriptases) or their unintended targets (host DNA polymerases), the compounds must undergo three cycles of phosphorylation to generate chain-terminating nucleoside triphosphates. For cases in which pro-drug activation is limiting for toxicity, simple loss-of-function mutations in pro-drug activation enzymes are expected to cause drug resistance, unless the enzymes are encoded by essential genes, while supersensitive mutants might be identified as specific gain-of-function alleles of pro-drug activating enzymes. The ability to select a resistant mutant as a simple loss-of-function allele is a tremendous advantage because the necessary mutagenized library size becomes equal to the number of nonessential genes.
Identifying drug-sensitive mutants from libraries of loss-of-function mutants has been facilitated by the preparation of nearly complete collections of yeast gene knockouts. For drug screens in which one wishes to query only nonessential genes, haploid yeast libraries can be used that will ultimately number around 5,000 strains, each carrying a deletion of a single nonessential gene. Typically, the gene-drug interactions that are discovered from such screens do not point directly to the target of the drug being screened but rather to a second cellular process that is rendered essential by treatment with a drug. By contrast, for drug screens in which one would like to embrace the full complement of nonessential and essential genes, libraries of yeast heterozygous diploid strains can be utilized that will ultimately number more than 6,000. Screening such heterozygous libraries typically identifies the drug target by a process termed drug-induced haploinsufficiency , but titration of a target by a drug may also render another gene or pathway 'synthetically' lethal.
Using a genetic-array-based method, Tucker and Fields  investigated the sensitivity of 4,800 haploid yeast strains, each containing a deletion of a different gene, to ibuprofen and three other drugs. After removing strains considered too sick for scoring drug effects and those that were sensitive to multiple drugs, the authors found a number of interesting gene-drug and pathway-drug interactions. Ibuprofen is widely used as a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase. The NSAIDs ibuprofen, indomethacin and sulindac sulfide, however, have been reported to reduce Alzheimer's disease and amyloidogenesis in a manner that does not involve cyclooxygenase , and it appears that the cancer chemopreventive effects of NSAIDs are not entirely due to cyclooxygenase inhibition . As yeast cells do not encode a cyclooxygenase but 50 μM ibuprofen is growth-inhibitory to wild-type strains, it was interesting to examine whether mutations in any nonessential yeast gene(s) conferred increased sensitivity to ibuprofen.
Remarkably, mutations in any of seven different genes involved in tryptophan biosynthesis conferred enhanced sensitivity to ibuprofen . It is important to note that this does not indicate that ibuprofen inhibits tryptophan biosynthesis - all of these strains are viable on rich media - but that loss of tryptophan synthesis coupled with the inhibitory effects of ibuprofen on another molecule is toxic. In fact, given the way this experiment was done, the existence of a deletion strain that is synthetically lethal or synthetically less viable with this set of strains could potentially identify the direct target of ibuprofen toxicity in yeast. Alternatively, overexpression-cloning could potentially identify the same molecule as an ibuprofen-resistant transformant.
Using a genetic arraying method, Baetz and co-workers , screened 5,000 heterozygous yeast mutants for sensitivity to dihydromotuporamine C, a compound used in preclinical development as an inhibitor of metastasis. These investigators did not exclude sick strains and identified 21 heterozygous mutants that exhibited the greatest drug sensitivity. Transferring the 21 identified strains to liquid cultures with and without drugs, they established that mutants heterozygous for two steps in sphingolipid metabolism were the most sensitive to dihydromotuporamine C. Turning to a candidate-gene approach, they then discovered four additional strains heterozygous for genes involved in sphingolipid metabolism that were drug-sensitive. Because, additionally, the drug reduced ceramide production in wild-type yeast and addition of 50 nM ceramide protected human breast carcinoma cell line MDA-231 from the drug, it appears that dihydromotuporamine C targets sphingolipid biosynthesis directly.
Using the barcoding method and a collection of 3,500 heterozygous yeast diploid strains, Lum and colleagues  screened 78 different drugs, the majority of which are approved by the US Food and Drug Administration (FDA) and are considered to have well-characterized targets. Among these drugs was the cancer chemotherapy agent 5-fluorouracil, which was shown more than 30 years ago to inhibit rRNA processing . Despite extensive studies of the drug's mechanism of action in fungal , fly  and human  systems, this information was nearly, but not entirely, forgotten  as investigators focused on the potential for 5-fluorouracil to function as a pro-drug of 5-fluoro-dUMP, a potent inhibitor of thymidylate synthetase . When Lum and colleagues tested heterozygous yeast strains for sensitivity to 5-fluorouracil, they found eight strains that were more sensitive than thymidylate synthetase heterozygotes; at least seven of these mutants are defective in rRNA processing, a result that not only reinvigorates studies of the mechanism of action of 5-fluorouracil but also suggests a number of new potential cancer targets.
Quantitative structure-activity relationship (QSAR) analysis is performed when a series of defined alterations in a small molecule are correlated with the read-out of an in vitro or in vivo assay of drug efficacy. When Giaever and co-workers  screened 10 different drugs against 5,900 heterozygous yeast strains by the barcoding method, they were surprised to find that dyclonine, fenpropimorph, and alverine citrate, which are described as an anesthetic, an agricultural anti-fungal, and a muscle relaxant, respectively, have nearly identical profiles of haploinsufficiency, with erg24, set6 and tvp18 heterozygotes being most sensitive. Furthermore, these investigators realized that the three drugs share a core substructure that may provide the genetic basis for their action. The haploinsufficiency profile can be considered an exquisitely sensitive qualitative (rather than quantitative) structure-activity relationship that maps chemical properties not onto pharmacological potencies but onto pathways. The degree to which the shared pathways in yeast underlie target or off-target effects in the use of these drugs can now be investigated.
In conclusion, although many high-throughput chemical screening methods were developed for enzyme-target-based assays, the parallelization of genetic and genomic methods have now made possible quantification of gene-drug interactions on previously unanticipated scales. As with other areas of genomics, the major challenge of chemical genomics is not to extend the number of experiments to the factorial limit of compounds, concentrations and strains, but rather to do the most penetrating validation and mechanistic experiments to extract the greatest insight from primary screens. Both genetic-array-based and barcode-based methods can suffer from systematic artifacts in which a particular deletion strain might have been misidentified or might contain unintended additional genetic changes that are or are not linked to the intended deletion. Thus, as more experiments are performed with existing yeast genomic libraries, accessible databases should be archived with the detailed findings of previous screens. Finally, standing on the shoulders of the yeast community, investigators developing mutant resources in Escherichia coli , Neurospora crassa  and vertebrate cells are advancing genetic array  and barcode [24, 25] methods for functional screens that will allow chemistry to interact with genomics across more branches of the tree of life.